Pharma and healthcare: sector news on Wednesday 18 November 2026
Average tone +5.7 (positive) across 5 companies with relevant coverage, from 76 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | +7.5 | 36 | Most coverage focused on US approval of Nelkarmi, the second lung cancer medicine to come from the Nuvalent acquisition, which advances its oncology push. |
| AstraZeneca | +7.0 | 29 | Coverage was mostly positive, centred on new US and EU approvals including Klygefa, a dismissed antitrust lawsuit and a Jefferies price target increase. |
| Haleon | +4.5 | 6 | Coverage focused on Haleon's push into India through low-priced packs and an Otrivin awareness campaign, plus a director buying shares with her own money. |
| Smith & Nephew | +4.8 | 3 | Coverage focused on Smith & Nephew's simpler strategy, alongside commentary on its last buyback tranche and its appeal as a watchlist name. |
| Convatec | +4.7 | 2 | Coverage centred on the appointment of a new chief financial officer from Fortrea, alongside commentary on whether the company can deliver on its plans. |
Strongest stories in the sector
- +10.0 Approved drug seen as having very large sales potential.
- +10.0 US regulator clears new weekly self-injected rare disease drug.
- +10.0 Second product from major acquisition gains US clearance.
- +10.0 Multiple approvals across several therapy areas.
- +10.0 Second approval from large acquisition supports its value.
- +10.0 Second approval from large acquisition supports its value.
- +10.0 Second acquired lung cancer drug clears regulator.
- +10.0 Regulatory clearance for second cancer medicine from acquired portfolio.
- +10.0 Approval bolsters its growing cancer franchise.
- +10.0 Approval from major deal adds to oncology line-up.
- +9.7 Acquisition delivers another marketed oncology product.
- +9.7 Second lung cancer product cleared following acquisition.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.